(Q33961524)

30 July 2017

1 reference

title

Adverse effects of antiepileptic drugs. (English)

1 reference

30 July 2017

Greenwood RS

1

1 reference

30 July 2017

publication date

1 January 2000

1 reference

30 July 2017

1 reference

30 July 2017

volume

41 Suppl 2

1 reference

30 July 2017

page(s)

S42-52

1 reference

Established antiepileptic drugs

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1157.2000.TB01523.X

Vigabatrin and behaviour disorders: a retrospective survey.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1157.2000.TB01523.X

Treatment of seizures and epilepsy in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1157.2000.TB01523.X

Valproic acid hepatic fatalities. III. U.S. experience since 1986.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1157.2000.TB01523.X

Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1157.2000.TB01523.X

The spectrum of Stevens-Johnson syndrome and toxic epidermal necrolysis: a clinical classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1157.2000.TB01523.X

Stevens-Johnson syndrome in patients on phenytoin and cranial radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1157.2000.TB01523.X

Clinically significant pharmacokinetic drug interactions between antiepileptic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1157.2000.TB01523.X

Valproic acid hepatic fatalities: a retrospective review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1157.2000.TB01523.X

Serum immunoreactive-leptin concentrations in normal-weight and obese humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1157.2000.TB01523.X

Obesity and endocrine disorders in women taking valproate for epilepsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1157.2000.TB01523.X

Valproate, lamotrigine, and insulin-mediated risks in women with epilepsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1157.2000.TB01523.X

The effects of valproate, carbamazepine, and oxcarbazepine on growth and sexual maturation in girls with epilepsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1157.2000.TB01523.X

Safety and efficacy of vigabatrin and carbamazepine in newly diagnosed epilepsy: a multicentre randomised double-blind study. Vigabatrin European Monotherapy Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1157.2000.TB01523.X

Metabolic changes during treatment with valproate in humans: implication for untoward weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1157.2000.TB01523.X

Serum leptin changes in epileptic patients who gain weight after therapy with valproic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1157.2000.TB01523.X

Specific changes in food intake elicited by blockade or activation of glutamate receptors in the nucleus accumbens shell

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1157.2000.TB01523.X

Felbamate for partial seizures: results of a controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1157.2000.TB01523.X

A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Topiramate YTC Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1157.2000.TB01523.X

10.1111/J.1528-1157.2000.TB01523.X

21 January 2018

Identifiers

DOI

1 reference

30 July 2017

1 reference